Skip to main content
Premium Trial:

Request an Annual Quote

UNC, Kerr Drug to Study PGx Program for Plavix

NEW YORK (GenomeWeb News) – Drug store chain Kerr Drug and the Eshelman School of Pharmacy at the University of North Carolina, Chapel Hill plan to investigate the feasibility of implementing a pharmacogenomic program at the community pharmacy level directed at Plavix (clopidogrel).

Under the six-month study announced today, the partners will jointly develop a protocol, evaluate physician and patients opinions, and research reimbursement challenges and regulatory requirements to such a program.

"Because pharmacists have unique expertise in medication use and are point-of-care service providers, they can play an important role in facilitating pharmacogenetic testing and more personalized health care,” Rebecca Chater, executive vice president of Kerr Health, said in a statement. "This study will examine just how that role can be implemented."

Participants in the study will be screened at the pharmacy, with results interpreted and reviewed by the prescribing physician and the pharmacist.

In 2010, the US Food and Drug Administration put a black-box warning on the antiplatelet drug Plavix saying the drug may not be effective for patients with certain variants of the CYP2C19 gene. FDA recommended a patient undergo genetic testing before being put on the drug.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.